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ABSTRACT
Mismatch repair (MMR) proteins are involved in maintaining genome integrity in
somatic and germline cells. Defects in MMR leads to various abnormalities, such as
tumorigenesis in Lynch syndrome (LS) and infertility. MLH1 (a central MMR protein)
along with other MMR proteins are involved in repair of replication-induced errors
arising due to inaccurate DNA polymerase. Compared to other genomic locations,
replication-induced errors occur at relatively higher frequency at microsatellites. If
unrepaired (due to defective MMR), these errors accumulate and give rise to a cellular
phenotype known as microsatellite instability (MSI). MSI is a hallmark of tumors
associated with LS and results from complete loss of MMR; LS patients have high
incidence of colorectal cancer.
It is still poorly understood why certain tissues in LS, in particular the gastrointestinal
(GI) tract, are more vulnerable to MSI-associated tumors. Also, how heterozygosity of
MMR genes impact the germline genomic integrity is not known. We hypothesized that
certain tissues, in particular those with high proliferating rates, are vulnerable to MMR
associated abnormalities compromising microsatellite stability (prior to complete loss
of MMR function) in a tissue-specific manner before tumorigenesis. Our aim was to
understand how MMR protein levels contribute to MSI in vivo.
In the research presented here, we used Mlh1 heterozygous mice (Mlh1+/- mice) as
model of LS to investigate how decreased MLH1 levels contribute to tissue-specific
MSI, and whether MSI is detectable prior to loss of MMR function and to neoplastic
growth. We tested MSI and measured MLH1 levels in primary cells derived from
different organs, focusing on the comparison between highly proliferating small
intestine and low proliferating spleen. Further, we tested MSI in sperm cells of Mlh1+/-
mice. In addition, we studied the association of loss of heterozygosity (LOH) and Mlh1
promoter methylation to tissue-specific MLH1 expression and MSI. The studies were
conducted at 4- and 12-month time point.
We discovered that highly proliferating normal tissues (small intestine and sperm) of
Mlh1+/- mice display MSI which increases with age, while low proliferating spleen was
microsatellite stable. Further, Mlh1+/- small intestine showed sporadic decrease in
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MLH1 levels which associated with the observed MSI, while Mlh1+/- spleens showed
expected MLH1 expression (i.e. approximately 50% of wildtype expression). We
observed soma-wide Mlh1 promoter methylation in a subset of Mlh1+/- mice; these
mice were the most vulnerable to MLH1 expression level decrease and to MSI in the
small intestine, while MLH1 expression in other somatic tissues remained unaffected.
In brief, we showed that normal small intestine of Mlh1+/- mice is particularly
susceptible to MLH1 depletion giving rise to MSI long before neoplasia. Further, we
demonstrated that Mlh1+/- sperm exhibit MSI which associates with germline Mlh1
promoter methylation.
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1. REVIEW OF THE LITERATURE
1.1. DNA Mismatch repair (MMR) in eukaryotes
MMR proteins, a class of DNA repair proteins, are responsible for the surveillance and
maintenance of DNA integrity. MMR proteins are involved in the repair of replication-
induced DNA damage such as base-base mismatches, small insertion-deletions
(indels) which arise due to the infidelity of DNA polymerases, and in processing of
induced (in mitotic cells) and cell-programmed (in meiotic cell) DNA double-stranded
breaks which are the most lethal type of DNA damage (Baker et al., 1996; McCulloch
& Kunkel, 2008; Pray, 2008; Shao et al., 2004; Thomas et al., 1991). In eukaryotes,
DNA polymerases has an error rate 1 × 10 7 per nucleotide (or less) on average in vivo
(Ganai & Johansson, 2016), most but not all of these DNA damages are repaired by
various cellular mechanisms, these mechanisms include proofreading function of DNA
polymerases (during replication), DNA mismatch repair system (post-replication repair)
and homologous recombination (double strand break repair) (Pray, 2008). Despite the
repair, during every cell division an average of 5 × 10 11 and 1.8 × 10 10 mutations per
nucleotide is introduced into human and Mus musculus genome, respectively (Drake,
Charlesworth, Charlesworth, & Crow, 1998), which reflects incomplete repair functions.
The MMR system in eukaryotes involves several mismatch repair proteins: MutS
homologs (MSH2, MSH3, MSH4, MSH5, and MSH6) and MutL homologs (MLH1,
MLH3, PMS1, and PMS2) (Wei, Kucherlapati, & Edelmann, 2002). Heterodimers
MSH2-MSH6 (MutS ) and MSH2-MSH3 (MutS ) recognize mismatches between the
nascent (i.e. newly synthesized) and the parental strand (MutS  recognizes base-base
mismatch and 1-bp indels, and MutS  recognizes 1-4 bp indels) (Boland & Goel, 2010;
Wei et al., 2002) (Figure 1). Heterodimers (primarily) MLH1-PMS2 (MutL ) and MLH1-
MLH3 (MutL ) are involved in repair of the mismatches in mitotic cells (Chen et al.,
2005; Wei et al., 2002) (Figure 1). In meiotic cells, MutL  is involved in repair of double
strand breaks that form during meiotic recombination (Rogacheva et al., 2014).
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Figure 1. Involvement of MMR proteins in repair of replication errors. Mismatches
and indel loops are recognized by MSH2-MSH6 (MutS ) and MSH2-MSH3 (MutS ).
MutS  and MutS  recruit MutL  (heterodimer MLH1-PMS2) which activates the
downstream repair events.
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1.2. Microsatellites and microsatellite instability (MSI)
Human and mouse genomes comprise of 50%-70% and up to 45% repetitive elements,
respectively (de Koning, Gu, Castoe, Batzer, & Pollock, 2011; Lu et al., 2020). One
class of repetitive elements is tandem repeats. As the name implies, the genomic
sequence in these repetitive elements is arranged in tandem repeat arrays. The
tandem repeats makeup 3% and 3-5% of the human and mouse genome, respectively
(Komissarov, Gavrilova, Demin, Ishov, & Podgornaya, 2011; Treangen & Salzberg,
2011). A subclass of tandem repeats is satellite DNA; microsatellites are the most
abundant type of satellite DNA (Dumbovic, Forcales, & Perucho, 2017) (Figure 2).
Microsatellites are defined as tandem repeat DNA sequence up to a total of 100
nucleotides in length, consisting of 1-6 bp (or 1-10 bp) repeat units (there is not yet a
consensus on the upper threshold of the repeat-unit size of a microsatellite) (Bois et
al., 1998; Fan & Chu, 2007; Richard, Kerrest, & Dujon, 2008; Yauk, Dubrova, Grant, &
Jeffreys, 2002).
Figure 2. Classification of tandem repeat DNA loci. Repetitive elements in DNA can
be divided into tandem and interspersed repeats. Shown is the sub-classification of
tandem repeats. Microsatellites belong to the class of satellite DNA.
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Due to their repetitive nature, microsatellites are highly prone to replication errors
(“replication slippage”) by DNA polymerase (error rate: 1 × 10 6 to 1 × 10 2 per locus
per generation) (Eckert & Hile, 2009; Ellegren, 2000, 2004; Fan & Chu, 2007). As a
consequence, DNA loops are formed at the microsatellites. In the presence of
proficient MMR, these DNA loops are repaired post-replication. In the absence of
MMR, in the subsequent round of DNA replication, these DNA loops give rise to de
novo insertion/deletion of repeat units at the microsatellites. This cellular phenotype is
referred to as microsatellite instability (MSI). Insertion at microsatellite occurs if the
DNA loop is formed on the newly synthesized strand, and deletion occurs if the DNA
loop is formed in the template strand (Fan & Chu, 2007) (Figure 3).
Various factors determine the mutability of a microsatellite, and some microsatellites
can be 100-fold more unstable than others (Eckert & Hile, 2009). The primary
determining factor of mutability of a microsatellite is its intrinsic features such as repeat
unit size, length of repeat array and sequence composition (Eckert & Hile, 2009; Fan
& Chu, 2007; Shah, Hile, & Eckert, 2010). Also, the genomic location of microsatellite
effects its mutability: exonic microsatellites accumulate less mutations as they are well
protected by MMR compared to intronic or intergenic microsatellites (Frigola et al.,
2017). Microsatellites are relevant study targets for two reasons: first, they are
sensitive indicators of MMR defects (Mead et al., 2007) and genotoxicity (Beal et al.,
2015; Fennelly, Wright, & Plumb, 1997), and second, when intragenic and mutated,
they can be the root cause of neoplasms and other diseases (Duval & Hamelin, 2002;
Markowitz et al., 1995).
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Figure 3. Schematic diagram of microsatellite instability (MSI). DNA polymerase
are prone to slippage at microsatellites. Misalignment of strands after slippage creates
a DNA loop. In the absence of MMR, the DNA loop remains unrepaired, and in the
subsequent DNA replication, the DNA loop is either copied (if the loop is formed on the
nascent strand) or omitted (if the loop is formed on the template strand), giving rise to
expansion or contraction of the microsatellite, respectively. The outcome is referred to
as MSI. Figure adopted and modified from (Fan & Chu, 2007).
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1.3. MMR, MSI and cancer
1.3.1. Lynch syndrome (LS)
Lynch syndrome (LS) is an autosomal-dominant cancer syndrome that accounts for
approximately 2%-5% of all colorectal cancer (CRC) (Duraturo, Liccardo, De Rosa, &
Izzo, 2019; Hampel et al., 2005; Wijnen et al., 1998). LS individuals have more than
80% and 43%-60% lifetime risk of developing CRC and endometrial cancer,
respectively (Burt, 2000). These individuals display early onset of CRC (average age
of 44 years) (Burt, 2000). Other types of cancers in LS tumor spectrum accounting to
a lifetime cancer risk of 1-13% includes stomach/gastric cancer, ovarian cancer,
hepatobiliary tract cancer, urinary tract cancer, small bowel cancer, brain/central
nervous system cancer and sebaceous neoplasm (Watson & Riley, 2005).
The LS individuals have a mono-allelic germline mutation in one of the MMR genes,
predominantly in MLH1 or MSH2 (in approximately 90% of LS cases), and occasionally
in other MMR genes (MSH2, MSH6, PMS2 or PMS1), MSH6 and PMS2 mutation
accounts for 10% of LS cases (Bonadona et al., 2011; Lynch & de la Chapelle, 2003).
Earlier, LS was known as hereditary nonpolyposis colorectal cancer (HNPCC) because
cancer incidence in these patients was thought to be confined to nonpolyposis CRC.
Over course of time, there were observations of incidence of other cancers in the
HNPCC patients, thus, the condition of monoallelic germline mutation in MMR genes
is currently referred to as LS. However the term HNPCC is not obsolete.
International conventions have set specific guidelines for LS diagnosis. These
guidelines have been updated/revised periodically to make LS diagnosis more
accurate, including better stratification of LS CRC cases from sporadic CRC cases. An
international convention held in Amsterdam in 1990 issued the first guideline for
HNPCC diagnosis named as Amsterdam criteria I. This guideline was limited to
diagnosis of nonpolyposis CRC. In 1990’s, HNPCC was better understood (example:
discovery of novel cellular phenotypes associated to HNPCC, and observation of other
CRC and non-GI tumors in HNPCC patients). In 1998, the Amsterdam criteria I was
revised to Amsterdam criteria II. For better LS diagnosis, later the Bethesda guidelines
were established, and revised in 2003. Amsterdam criteria II, and revised Bethesda
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guidelines are listed in Table 1. A notable addition to the Bethesda guidelines was
inclusion of MSI criterion.
Table 1. Guidelines for LS diagnosis. Amsterdam criteria II (Vasen, Watson,
Mecklin, & Lynch, 1999) is listed above, and revised Bethesda guideline is listed below
(Umar, Risinger, Hawk, & Barrett, 2004)
Amsterdam criteria II (1998) *
There should be at least three relatives with HNPCC-associated cancer, with one relative being a
first-degree relative of the other two
At least two successive generations should be affected
At least one individual should be diagnosed before the age of 50 years
Familial adenomatous polyposis CRC should be excluded
Tumors should be verified by pathological examination
Revised Bethesda guideline (2003) **
CRC should be diagnosed before the age of 50 years
Presence synchronous or metachronous colorectal or other HNPCC-related tumor regardless of age
CRC with a MSI-high (MSI-H) morphology diagnosed before the age of 60 years
CRC with one or more first-degree relatives with CRC or other HNPCC-related tumors. One of the
cancers must have been diagnosed before the age of 50 years (with exception to adenoma, which
must have been diagnosed before the age of 40 years)
CRC with two or more relatives with CRC or other HNPCC-related tumor, regardless of age.
* all criteria need to be fulfilled, ** only one criteria needs to be fulfilled
1.3.2. LS (suspected) patients
There are individuals, categorized as LS (suspected) patients, who have similar
clinicopathological phenotypes as LS patients (i.e. early onset of colorectal and
endometrium cancer, and MMR deficient and MSI-H tumors), however they do not
have germline deleterious MMR mutations. Instead, the LS (suspected) patients have
a germline epigenetic MMR defect (primarily Mlh1 promoter methylation) (Niessen et
al., 2009). The LS (suspected) cases sum up to 0.6-13% of the total LS patients
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(Niessen et al., 2009). The LS (suspected) patients show soma-wide Mlh1 methylation
phenotype, i.e. Mlh1 promoter methylation in multiple tissues. These tissues include:
blood, peripheral blood leukocytes (PBLs), buccal mucosa, hair follicles, saliva, colon
mucosa, endometrium, gastric mucosa, small bowel, skin fibroblasts, and sperm
(Damaso et al., 2019; Gazzoli, Loda, Garber, Syngal, & Kolodner, 2002; Goel et al.,
2011; Hitchins, 2013; Hitchins et al., 2007; Kanaya et al., 2003; Miyakura et al., 2004;
Morak et al., 2008; Niessen et al., 2009; Suter, Martin, & Ward, 2004).
1.3.3. MSI phenotype in LS: a hallmark of LS-associated cancer
Almost all (more than 90%) of LS- associated tumors show MSI (Aaltonen et al., 1993;
Aaltonen et al., 1994; Pedroni et al., 1999; Thibodeau, Bren, & Schaid, 1993). MSI
phenotype was first reported in LS tumors in 1993 (Aaltonen et al., 1993), Aaltonen et.
al. showed the RER+ (replication error) phenotype by assaying MSI at seven
microsatellite loci. They proposed RER+ phenotype as a valuable tool for LS-
associated cancer diagnosis, especially incase of incomplete family CRC history, and
for better stratification of the LS-associated CRC versus the sporadic CRC, which now-
a-days is implemented in the Bethesda guidelines as the MSI assay. As per Bethesda
guidelines, a standard MSI panel includes 5 microsatellites: BAT25, BAT26, D2S123,
D5S346 and D17S250; depending on MSI at two or more, one or none of the 5
microsatellites, a tumor is classified as MSI-high (MSI-H), MSI-low (MSI-L) or
microsatellite stable (MSS), respectively (Umar, Boland, et al., 2004).
Tumors in LS are MMR-deficient and display high levels of MSI (Hemminki et al.,
1994), which led to the notion that MSI in LS-associated CRC follows Knudson’s two-
hit hypothesis of tumorigenesis (Knudson, 1971). According to this model, the “first hit”
is inherited as a germline defect in an MMR gene, and the “second hit” makes the
remaining functional MMR allele defective (either by a genetic (LOH and/or deleterious
mutations) or by an epigenetic (gene silencing by promoter methylation) process)
thereby completely losing the MMR function, and as consequence cancer cells exhibit
the MSI mutator phenotype (Hemminki et al., 1994; Peltomaki, 2014).
MSI, as reported by the microsatellite markers, confer the global genome instability.
However, for a microsatellite to instigate tumorigenesis MSI should occur at
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microsatellite located inside a gene; genes that contain intragenic microsatellites are
called MSI-target genes. MSI in MSI-target genes may lead to frameshift mutations,
giving rise to dysfunctional proteins that affect various regulatory pathways such as
cell cycle, cell proliferation, apoptosis and DNA repair, giving selective advantage to
cells and making them tumorigenic (Duval & Hamelin, 2002; Vilkki et al., 2002). The
first MSI-target genes to be described in MSI-H CRC, and the ones extensively studied
are: tumor suppressor genes TGF RII and IGFIIR, apoptosis regulator BAX, and MMR
genes MSH6 and MSH3 (Duval & Hamelin, 2002; Markowitz et al., 1995). In recent
years, more MSI-target genes with possible roles in tumorigenesis has been described,
including gene encoding tumor suppressor protein PTEN, MMR protein MLH3, DNA
repair protein RAD50 and DNA damage response protein CHK1 (Duval & Hamelin,
2002). Because of the severity of intragenic mutations (which could lead to
catastrophic consequences, for example tumorigenesis), intragenic regions (primarily
exons) are more efficiently protected by MMR compared to other genomic regions
(Frigola et al., 2017). This preferential MMR activity is due to enriched histone marks
H3K36me3 (Histone H3 trimethylation at lysine 36) in the exons which facilitate
recruitment of MutS  (MMR heterodimer responsible for mismatch-recognition)
(Frigola et al., 2017).
1.4. DNA methylation and Loss of heterozygosity (LOH)
DNA methylation is a major epigenetic modification which preferentially occurs at a CG
dinucleotide (a cytosine nucleotide followed by a guanine nucleotide in a 5  to 3
orientation), termed as CpG sites (i.e. C-phosphate-G), or simply CG sites. CpG sites
are said to have undergone methylation when a methyl group is covalently attached to
the C5 position of cytosine nucleotide to form 5-methylcytosine (5-mC) (Holliday &
Pugh, 1975).
Regions of the genome with high density of CpG (GC content of more than 50%, and
an observed/expected ratio of CpG to GpC greater than 0.6) are called CpG islands,
CpG islands are 300-3000 bp in size (Antequera & Bird, 1993; Long, Smiraglia, &
Campbell, 2017). There are approximately 45,000 and 37,000 CpG islands per haploid
genome in human and in mouse, respectively (Antequera & Bird, 1993). 55.9% and
21
46.9% of all genes in human and mouse, respectively, are associated with CpG islands
(Antequera & Bird, 1993). Within a gene, abundance of CpG islands is the highest in
the core promoter. Methylation of CpG islands in the promoter region of a gene is
known to suppress gene expression, specifically hypermethylation of CpG islands in
the core promoter (promoter region nearest to the start codon containing the DNA
polymerase binding site, TATA box and transcription start site (TSS)) is known to
silence a gene (Saxonov, Berg, & Brutlag, 2006). DNA methylation is essential for
development and tissue-specific gene expression, however, aberrant promoter
methylation of key regulatory genes, e.g. tumor suppressor genes, is pathogenic and
can lead to several diseases including cancer (Jones & Baylin, 2007).
LOH is a common genetic mechanism leading to inactivation of tumor suppressor
genes in an inherited cancer predisposition with mono-alleleic germline mutation (eg.
MMR genes in LS). The only functional allele of tumor suppressor gene is lost due to
LOH making the gene nonfunctional which leads to tumorigenesis (Ryland et al.,
2015). LOH are large structural alterations encompassing loss of part of a chromosome
to loss of entire chromosome (Thiagalingam et al., 2001). Mechanisms leading to LOH
include genetic recombination, break-induced replication, gene conversion, mitotic
nondisjunction and chromosomal segment loss due to deletion events (Thiagalingam
et al., 2001).
1.5. MMR and fertility
1.5.1. Spermatogenesis
Spermatogenesis is the process of differentiation of spermatogonia (spermatogonial
stem cells (SSCs)) into haploid spermatozoa (the male gametes). In mice,
undifferentiated Asingle spermatogonia (As) undergo up to 10 rounds of mitosis to
produce primary spermatocytes, and the primary spermatocytes undergoes a two-step
meiosis cell division (meiosis I and II) to give rise to sperm cells (Figure 4). With this
division rate, a single As should give rise to 4096 sperm cells. Around 50% of cells
undergo apoptosis in the spermatogenesis process, but even so, 40 million sperm are
generated per gram of testis tissue per day in mice (Fayomi & Orwig, 2018). In
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comparison, in human, the undifferentiated SSC undergoes five divisions (three mitotic
and two meiotic) producing approximately 4.4 million sperm cells per gram of testis
tissue per day (Fayomi & Orwig, 2018).
Figure 4. Schematic diagram of spermatogenesis in mice. During
spermatogenesis, a single spermatogonial stem cell (Asingle spermatogonia) undergoes
up to 12 transit cell divisions to give rise to roughly 4000 spermatids. Numbers below
the spermatogonial sub-stages indicate the cell count at that sub-stage. As, Asingle
spermatogonia; Apr, Apaired spermatogonia; Aal, Aaligned spermatogonia; A1, A1
spermatogonia; A2, A2 spermatogonia; A3, A3 spermatogonia; A4, A4 spermatogonia;
Aint, Intermediate spermatogonia; B, B spermatogonia. Figure modified from (Fayomi
& Orwig, 2018).
1.5.2. Role of MMR in spermatogenesis
Spermatogenesis involves a high rate of cell proliferation up to 12 transit amplifying
divisions (10 mitotic, followed by two meiotic cell divisions) of a single spermatogonial
stem cell. With this high rate of cell division, maintaining the genomic integrity
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throughout spermatogenesis is crucial, especially as any DNA aberration in the sperm
cells can be inherited to the next generation. Therefore, the role of MMR in
spermatogenesis is critical. During spermatogenesis, MMR proteins are involved in
post-replicative DNA repair in pre-meiotic germline cells, and in meiotic recombination
and gametogenesis in meiotic cells. As in somatic cells, in pre-meiotic germline cells
MMR proteins MLH1, PMS2, MSH2, MSH3 and MSH6 are involved in repairing indel
mutations and single base pair mismatches. In meiotic cells, MMR proteins MLH1,
MLH3, MSH4 and MSH5 are essential to complete meiotic crossovers and for
gametogenesis (Baker et al., 1996; de Vries et al., 1999; Edelmann, Cohen, et al.,
1999; Gunes, Al-Sadaan, & Agarwal, 2015; Kneitz et al., 2000; Lipkin et al., 2002; Wei
et al., 2002). In the germline, MMR defects lead to failure in spermatogenesis and
oogenesis and dysfunctional sperm and oocytes, and can even lead to infertility in
human and mice (Baker et al., 1996; Gunes et al., 2015; Lipkin et al., 2002; Mukherjee,
Ridgeway, & Lamb, 2010).
1.6. Mouse model for MMR
Mouse models have been extensively used to study eukaryotic MMR and MMR-
associated phenotypes. Several mouse models resembling the MMR deficiency in
human have been created from the late 1990’s to early 2000’s. These includes mouse
models for MutS homologs: Msh2 (Lin et al., 2004), Msh3 (de Wind et al., 1999), Msh5
(de Vries et al., 1999; Edelmann, Cohen, et al., 1999), Msh6 (de Wind et al., 1999;
Yang et al., 2004) and mouse models for MutL homologs: Mlh1 (Baker et al., 1996;
Edelmann et al., 1996), Mlh3 (Lipkin et al., 2002), Pms1 (Prolla et al., 1998), Pms2
(Baker et al., 1995). The table below lists widely used MMR (gene knock-out) mouse
models along with severity status of MSI, cancer incidence and the effect on fertility.
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Table 2. MMR knock-out mouse models and their severity status of molecular (MSI)








knock-out MSI cancer fertility
MutS Msh2 -/- severe severe no effect
(de Wind, Dekker, Berns, Radman, & te Riele,
1995; Egashira et al., 2002; Reitmair et al., 1995)
Msh3 -/- moderate moderate no effect (de Wind et al., 1999; Edelmann et al., 2000)
Msh4 -/- no effect no effect severe (Kneitz et al., 2000)
Msh5 -/- no effect no effect severe
(de Vries et al., 1999; Edelmann, Cohen, et al.,
1999)
Msh6 -/- moderate moderate no effect (Edelmann et al., 1997)
MutL Mlh1 -/- * severe severe severe
(Edelmann, Yang, et al., 1999; Kawate et al., 1998;
Prolla et al., 1998)
Mlh3 -/- moderate severe moderate (Chen et al., 2005)
Pms1 -/- nominal no effect moderate (Prolla et al., 1998)
Pms2 -/- severe severe severe (Prolla et al., 1998)
* Mlh1 mice with different Mlh1 gene dosage (i.e. Mlh1+/+, Mlh1+/- and Mlh1-/-) were used in studies
presented in this thesis.
1.6.1. Mlh1+/- mice as a model for Lynch syndrome
Mlh1 mice are good animal models to study the relationship between MMR gene
dosage and the subsequent genomic instability and tumor incidence. Mlh1
heterozygous (Mlh1+/-) and Mlh1 homozygous (Mlh1-/-) mice carry germline mono-
and bi-allelic deleterious mutation in the Mlh1 gene, respectively, which mimics the
germline MMR status of LS syndrome (see section 1.3.1) and constitutional mismatch
repair-deficiency (CMMRD) syndrome in human, respectively (Edelmann et al., 1996;
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Tabori et al., 2017). CMMRD patients carry germline bi-alleleic deleterious mutation in
one of the MMR genes, primarily PMS2 and MSH6.
Mlh1-/- mice has been extensively studied for the MSI phenotype and tumor incidence.
The tumor spectrum in Mlh1-/- mice spans primarily GI tract and hematological
malignancies, and skin cancers (Prolla et al., 1998). Median age of onset of cancer in
Mlh1-/- mice is before 7 months (Edelmann, Yang, et al., 1999; Tabori et al., 2017). In
human, the median age of onset of first cancer in CMMRD patient is 7.5 years (versus
67 years in a healthy person). Most common tumors in CMMRD patients are brain
tumors, followed by GI-tract and hematologic malignancies, CMMRD patients also
develop LS-associated malignancies (Tabori et al., 2017).
LS patients have high incidence and early onset of CRC and endometrial cancer (see
section 1.3.1). In mouse model of LS (Mlh1 +/- mice) the median age of onset of cancer
is before 9.8 months, and tumorigenesis affects primarily GI tract and hematological
tissues (Edelmann, Yang, et al., 1999). However, the tumor incidence in Mlh1+/- mice
is considerably low, with a wide range reported in various studies from 1% to 32%
(1.1% (1 of 88 Mlh1+/- mice) (Tokairin et al., 2006), 9% (3 of 32 Mlh1+/- mice) (Fu et
al., 2009) and 32% (7of 22 Mlh1+/- mice) (Edelmann, Yang, et al., 1999). In GI tract of
Mlh1 +/- mice, tumors were observed in the duodenum, jejunum, and colon (Edelmann,
Yang, et al., 1999). In Mlh1-/- mice, tumors are observed in all parts of the GI tract
(jejunum and ileum being the most frequent sites for tumorigenesis) (Edelmann, Yang,
et al., 1999; Prolla et al., 1998). In addition, both male and female Mlh1-/- mice are
infertile, while Mlh1+/- mice are fertile (Baker et al., 1996).
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1.6.2. The mouse small intestine
The small intestine in mouse is approximately 30 cm in length stretching from the
stomach on the proximal end to caecum on the distal end. It can be divided into three
distinct regions: proximal duodenum, middle jejunum and distal ileum (Figure 5A). The
mucosa of small intestine consists of columnar epithelium which forms villi and
intestinal crypts. Villi are finger-like absorptive projections facing towards the lumen,
composed of terminally differentiated cells (enterocytes, goblet cells and
enteroendocrine cells). Crypts consist of undifferentiated LGR5+ intestinal stem cells
(ISCs) which reside at the very base of the crypt and are sandwiched between
differentiated Paneth cells. Crypts also contain transit amplifying (TA) cells (Li &
Jasper, 2016) (Figure 5A). Actively dividing LGR5+ ISCs either self-renew, or
generate progenitor TA cells. The highly proliferating TA cells undergo two to five
divisions and gradually differentiate and migrate from crypt to villi (Barker, 2014; Li &
Jasper, 2016) (Figure 5B). There are reserve stem cells which are localized at the +4
position from the base of the crypt called the +4 stem cells, these cells can also self-
renew, proliferate and generate different cell lineages of the small intestine, however
they remain quiescent and are activated only in case of intestinal injury (Barker, 2014).
Small intestine is a highly proliferating tissue. In mice, more than 300 million new
epithelial cells are generated every day to compensate for the high rate of cell death
on the villi (with a turnover rate of 3-5 days). This is repeated several hundred times
during the lifespan of an inbred mouse (which has average life span of 2-year) (Barker,
2014), and all these cells originate from ISCs. Tumor incidence in the GI tract of MMR-
deficient mice preferentially affects the small intestine (Prolla et al., 1998) unlike in the
colon in the human. Thus, in MMR mouse models, small intestine is the relevant tissue
to study the cellular and molecular phenotypes related to GI tumorigenesis in human.
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Figure 5. Murine small intestine and the associated intestinal stem cell (ISC)
lineages. (A) Anatomy of the mouse small intestine. Mouse small intestine can be
divided into three regions: duodenum, jejunum and ileum. A cross-section of small
intestine shows multiple layers: namely serosa, muscularis, submucosa and mucosa.
Mucosa (the internal lining) consists of villus-crypt units. The crypt contains ISCs and
Paneth cells, villus consists of terminally differentiated cells. (B) ISC lineages
(modified from (Sancho, Cremona, & Behrens, 2015)) ISCs either self-renew or give
rise to highly proliferating progenitor transit amplifying (TA) cells. TA cells terminally
differentiate into specialized cells.
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2. AIM OF THE STUDY
The principal aim of the study was to understand how MMR protein levels contribute
to MSI in vivo.
Specific aims of the projects were:
Study I. To test tissue-specific Mlh1 haploinsufficiency in Mlh1+/- somatic tissues with
various proliferation rates in vivo.
Study II. To investigate the effect of Mlh1 heterozygosity and Mlh1 promoter
methylation on sperm MSI.
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3. MATERIALS AND METHODS
Table 3. List of methods used in the original publications
Method Publication
Mlh1 genotyping I, II
Single-molecule MSI analysis by PCR I, II
RNA expression analysis using qPCR I
Western blot analysis I
Immunohistochemistry (IHC) and IHC image analysis I
methylation analysis by methylation-specific PCR (MSP) I, II
Loss of heterozygosity (LOH) analysis by PCR I
Statistical analysis I, II
3.1. Mice and genotyping
Mlh1 mice (B6.129- Mlh1tm1Rak, strain 01XA2, National Institutes of Health, Mouse
Repository, NCI Frederick) (Edelmann et al., 1996) were used in the studies. In
B6.129- Mlh1tm1Rak mice, exon 2 of the 129S1/SvImJ allele is replaced by a neo
cassette making the allele nonfunctional.
Mlh1 genotyping was performed using DNA lysate from earpieces. DNA lysate was
prepared using 100 l of lysis buffer (50 mM KCl, 10 mM Tris-HCl pH 8.3, 2.5 mM
MgCl2, 0.1 mg/mL gelatin, 0.45% NP-40, 0.45% Tween20) supplemented with 20 g
proteinase K. Cells were lysed overnight at 56°C, and the next day proteinase K was
inactivated by boiling for 10 minutes. 0.5 l of DNA lysate was used for genotyping
PCR, PCR was performed in Platinum green hot start PCR master mix (Invitrogen,
Carlsbad, CA) using Mlh1 genotyping primer published at the Frederick national
laboratory’s mouse repository website, namely: M001: 5'-
TGTCAATAGGCTGCCCTAGG-3', M002 :5'-TGGAAGGATTGGAGCTACGG-3',
M003: 5'-TTTTCAGTGCAGCCTATGCTC-3'. Primer combination M001/M002
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amplified the knockout allele, and M001/M003 amplified the wildtype allele which had
PCR product size of 500 bp and 350 bp, respectively. The following PCR program was
used: 2 min at 94°C, 38 cycles of 30 sec at 98°C, 30 sec at 55°C and 45 sec at 72°C,
followed by 5 min at 72°C.
3.2. Mouse husbandry, sample collection and preparation
The mice were bred and maintained following Animal Experiment Board in Finland and
Laboratory Animal Centre of the University of Helsinki regulations and guidelines. Mice
were humanely euthanized using CO2 inhalation and cervical dislocation. Tissues
(except of small intestine) were harvested, snap-frozen and stored at - 80°C until
further use. The small intestine was flushed with cold PBS, opened longitudinally,
rinsed with cold PBS and inspected for tumors visible to the naked eye. A 3 cm tissue
piece was cut from the center of small intestine (approximately 15 cm from the pyloric
sphincter), which comprises the jejunum section of the small intestine. This piece of
jejunum was inspected for any obvious tumor-like outgrowths using a stereoscope,
thereafter snap-frozen and stored at - 80°C. Frozen tissues were used for subsequent
DNA, RNA and protein analysis. Only normal (tumor-free) tissues were used for the
experiments.
3.3. Single-molecule MSI analysis by PCR
3.3.1. DNA preparation
For somatic tissues, approximately 2-5 mg of tissue was used for DNA extraction. Each
tissue piece was finely chopped and homogenized using a 20G needle and syringe,
thereafter, DNA was extracted using AllPrep DNA/RNA Mini Kit (Qiagen, Hilden,
Germany) according to manufacturer’s instruction. For sperm cells, prior to DNA
extraction, we performed differential lysis for sperm cell enrichment, to obtain a sperm
cell purity of over 95%. This was accomplished using previously published protocol
(Zhang, Monckton, Siciliano, Connor, & Meistrich, 2002). Sperm cells were collected
from cauda epididymides. The sperm DNA was extracted using DNeasy Blood &
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Tissue Kit (Qiagen) following manufacturer’s instruction. DNA quantification was
performed using a Qubit fluorometer (Thermo Fisher Scientific, Waltham, MA). A
working DNA dilution was made by diluting the stock DNA to a dilution of (theoretical)
5 DNA molecule concentration, i.e. 30 pg/μl and 15 pg/μl (considering weight of 3
pg/haploid mouse genome (Laird, 1971)) for diploid and haploid genome, respectively
in 5 mM Tris-HCl (pH 7.5) supplemented with 5 ng/μl carrier herring sperm DNA
(Thermo Fisher Scientific). For each working DNA dilution to be analyzed, using a
dilution series, we determined the concentration that yielded 50% PCR success rate
for the microsatellites assayed. By Poisson approximation this PCR success rate
equates to approximately one amplifiable molecule per positive PCR reaction (Beal et
al., 2015; Yauk et al., 2002).
3.3.2. Microsatellites assayed
We tested MSI at three microsatellite loci: two mononucleotide repeats A27 and A33
(Kabbarah et al., 2003), and one dinucleotide repeat D14Mit15 (Edelmann et al.,
1996). The dilution series experiment followed by Poisson approximation (see section
3.3.1) was performed separately for each of the three microsatellites. A27 is an
intergenic microsatellite located approximately 2 kb downstream of the Epas1 gene,
A33 is an intronic microsatellite within Epas1 gene (between exons 2 and 3), and
D14Mit15 is an intergenic microsatellite at 40 kb distance from the nearest gene
Ptpn20.
3.3.3. PCR and capillary electrophoresis
PCR was performed using Q5 High-Fidelity DNA Polymerase system (New England
Biolabs, Ipswich, MA) (supplemented with 1 ng/μl carrier herring sperm) in a 10 μl
reaction volume. PCR primers used in the MSI assay were as follows: for A27, A27_F
5´ 6-FAM- TCCCTGTATAACCCTGGCTGACT 3´ and A27_R 5´
GCAACCAGTTGTCCTGGCGTGGA 3´, for A33, A33_F 5´ VIC-
TACAGAGGATTGTCCTCTTGGAG 3´, A33_R 5´ GCTGCTTCACTTGGACATTGGCT
3´, for D14Mit15, D14Mit15_F 5´ NED TTGGCTGCTCACTTGCAG 3´ and
D14Mit15_R 5´ TTACCCTCCCCATAACTCCC 3´ (Edelmann et al., 1996; Kabbarah et
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al., 2003). A concentration of 0.5 μM, 0.2 μM and 0.1 μM of forward and reverse
primers were used for A27, A33 and D14Mit15, respectively. Two microsatellites, A33
and D14Mit15, were duplexed in a single PCR reaction, and a separate PCR reaction
was run for A27. For the A33 and D14Mi15 duplexed PCR, we used the following PCR
program: 30 sec at 98°C, 35 cycles of 10 sec at 98°C, 30 sec at 66°C, 5 sec at 72°C,
followed by 2 min at 72°C. For A27, the following PCR program was used: 30 sec at
98°C, 35 cycles of 10 sec at 98°C, 30 sec at 70°C, 5 sec at 72°C, followed by 2 min at
72°C. Capillary electrophoresis, using ABI3730xl DNA Analyzer (Thermo Fisher
Scientific), was performed to analyze the DNA fragments.
3.3.4. Fragment analysis and mutant scoring
Fragment analysis was performed using Fragman R package (Covarrubias-Pazaran,
Diaz-Garcia, Schlautman, Salazar, & Zalapa, 2016). Stringent criteria for true
microsatellite signal calling was used, hence the mutation rates reported here are likely
a conservative estimate. Mutant scoring criteria can be read in Study II.
For each microsatellite assayed, MSI was separately scored for insertions and
deletions. We considered the step-wise mutation model for MSI which assumes
mutations at microsatellites occur as single repeat-unit changes (Ohta & Kimura,
1973). MSI rate was calculated as follows:
MSI rate = total no. of single repeat-unit shifts observed/total DNA molecules analyzed
In study II, MSI rate is presented as percentage.
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3.4. RNA expression analysis using quantitative PCR
RNA used for qPCR was extracted in parallel with genomic DNA, from the same tissue
piece, using AllPrep DNA/RNA Mini Kit (Qiagen) as per manufacturer’s instructions.
Concentration of RNA was measured using NanoDrop 1000 spectrophotometer
(Thermo Fisher Scientific, Waltham, MA). cDNA was synthesized from 500 ng of RNA
using SuperScript VILO cDNA Synthesis Kit (Invitrogen). 15 ng of cDNA was used to
perform qPCR, using SsoAdvance Universal SYBR Green Supermix system (Bio-Rad,
Hercules, CA) using following PCR program: 30 sec at 95°C, 40 cycles of 10 sec at
95°C, 30 sec at 60°C, and 5 sec at 72°C. The PCR plates were read for SYBR green
signal after every PCR cycle. Primers used for qPCR were as follows: for Mlh1, Mlh1_F
5´ GGGAGGACTCTGATGTGGAA 3´ and Mlh1_R 5´ AGAGCTTGGTCTGGTGCTGT
3´ (amplicon size: 216 bp), and for Beta-actin, beta-actin_F 5´
AGACTTCGAGCAGGAGATGG 3´ and beta-actin_R 5´
AGGTCTTTACGGATGTCAACG 3´ (amplicon size: 310 bp). cDNA from Mlh1+/+ and
Mlh1-/- tissues were used as positive and negative control for Mlh1 expression,
respectively. Gene expression data of Mlh1 was normalized to beta-actin. Data was
analyzed using Bio-Rad CFX Maestro (version 1.1) and is presented as % wildtype.
3.5. Protein expression analysis
3.5.1. Western blot analysis
The frozen tissue pieces were thawed on ice, mechanically homogenized and
incubated in RIPA buffer (supplemented with protease inhibitor cocktail (Roche, Basel,
Switzerland)) for 30 minutes on ice. Thereafter, the protein lysate was centrifuged for
10 minutes at 14000 rpm (at 4°C), the supernatant was collected to a separate tube
and stored at - 80°C until further use. Protein concentration was measured using
Pierce™ BCA™ protein assay kit (Thermo Fisher Scientific). Western blotting was
performed with 30 μg of denatured protein. The protein was run on a 4–20% Mini-
Protean TGX gel (Bio-Rad). Using Trans-Blot Transfer Pack (Bio-Rad), protein was
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transferred from the gel to 0.2 μm nitrocellulose membrane. Ponceau staining (5
minutes at room temperature) was performed to confirm complete protein transfer to
the membrane. 5% milk in PBS supplemented with 1μl/ml Tween-20 (Thermo Fisher
Scientific) was used to block the membrane. Blocking was done for 1 hour at room
temperature. After blocking, the membranes were incubated overnight at 4°C with
primary antibodies against the candidate proteins. The next day, for protein detection,
the membranes were incubated with infrared secondary antibodies for 1 hour at room
temperature and then scanned with LI-cor Odyssey FC system (LI-COR, Nebraska,
USA). Image analysis was performed using LI-cor Image Studio lite (version 5.2). The
following antibodies were used for protein detection: primary antibodies against MLH1
(ab92312, Abcam, dilution 1:1000) and Beta-actin (A5441, Sigma, dilution 1:5000),
secondary antibodies IRDye 800CW (926-32211, Li-cor, dilution 1:5000) and IRDye
680RD (926-68070, Li-cor, dilution 1:5000). The MLH1 protein signal intensities were
normalized to Beta-actin signal intensity.
3.5.2. Immunohistochemistry (IHC) and IHC image analysis
The “Swiss roll” technique was used to embedded the small intestine into paraffin
blocks (Moolenbeek & Ruitenberg, 1981). Prior to embedding, the small intestine was
flushed with cold 1xPBS, fixed overnight with 4% paraformaldehyde, and cut open
longitudinally. 4μm thick sections of the Swiss roll were used for IHC. For IHC, antigen
retrieval was performed by heating the slides in 10mM citrate buffer (pH 6) for 20
minutes, followed by staining with antibody against MLH1 (anti- MLH1 antibody, cat.
no. ab92312, clone EPR3894, Abcam, Cambridge, UK, dilution 1:1500 dilution).
Thereafter, slides were stained with BrightVision Poly HRP goat anti-rabbit IgG (cat.
no. DPVR55HRP, ImmunoLogic, Duiven, The Netherlands) and counterstained with
hematoxylin-eosin. 3DHistech Panoramic 250 FLASH II digital slide scanner
(3DHistech, Budapest, Hungary) was used to scan the slide at 20X magnification.
CaseViewer (version 2.2) was used to visualize the slides. Image quantification was
done using IHC Profiler in ImageJ (Varghese, Bukhari, Malhotra, & De, 2014).
Approximately, 50 villus-crypt units per jejunum from five randomly selected sites was
quantified for the staining intensity.
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3.6. Methylation-specific PCR (MSP) and LOH assay
MSP (Herman, Graff, Myohanen, Nelkin, & Baylin, 1996) was performed to investigate
methylation status of the Mlh1 promoter. 500 ng of genomic DNA was bisulfite-
converted using EZ DNA Methylation-Direct Kit (Zymo Research). 1 l of bisulfite-
converted DNA was used for MSP, MSP was performed using 2xZymo Taq premix
system (Zymo research). Two parallel PCR reaction, one with primers specific to
methylated CpG site and other with primers specific to unmethylated CpG site was
performed. For study I following primer were used: primers specific to methylated CpG
site: forward primer 5´ GGTGTACGAAGTTATTTTTATTTTAGTC 3´ and reverse
primer 5´ ACCCAACGATACCTAATAATAAAACC 3´ (Zymo Research, Irvine, CA,
catalog no. D2012), and primers specific to unmethylated CpG site: forward primer 5´
GGTGTATGAAGTTATTTTTATTTTAGTT 3´ and reverse primer 5´
ACCCAACAATACCTAATAATAAAACC 3´. For study II previously published primers
were used for MSP (Fraga et al., 2004), which were as follow: primers specific to
methylated CpG site: forward primer 5´ GAATTTGAGCGTGAGGAGTTC 3´, reverse
primer 5´ TAACCGACCGCTAAATAACTTCC 3´ and primers specific to unmethylated
CpG site: forward primer 5´ AGAATTTGAGTGTGAGGAGTTT 3´ and reverse primer
5´ CCAACCACTAAATAACTTCCC 3´. Following PCR program was used in study I: 10
sec at 95°C, 40 cycles of 30 sec at 95°C, 45 sec at 58°C, and 60 sec at 72°C, and final
extension for 7 min at 72°C. For study II, following PCR program was used: 10 sec at
95°C, 40 cycles of 30 sec at 95°C, 30 sec at 62°C, and 60 sec at 72°C, and final
extension for 7 min at 72°C. PCR products were run on an agarose gel and visualized
under UV in presence of ethidium bromide. Methylation status was scored qualitatively
based on presence or absence of PCR product in PCR reactions with primers specific
to methylated CpG site.
LOH at Mlh1 was tested using restriction fragment length polymorphism (RFLP) assay
targeting the 3´ and the 5´ ends of the Mlh1 gene, which covered exon 1 and 19 of the
Mlh1 gene, respectively. DNA from Mlh1+/+ and Mlh1-/- tissues were used as wildtype
and knockout allele controls, respectively. 50 ngs of DNA was used for PCR. PCR was
performed using Phusion High-Fidelity DNA Polymerase system (Thermo Fisher
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Scientific) and the following PCR condition: 30 seconds at 98°C, 35 cycles of 10 sec
at 98°C, 20 sec at 70°C and 120 sec at 72°C, and final extension of 10 min at 72°C.
For exon 1 region, following primers were used: forward primer 5´
GGCTTACCTGCCAGCACAACC 3´ and reverse primer 5´
CCGTGTGCATAATGGGAAACC 3´, and for the exon 19 region following primers were
used: forward primer 5´ GAGTATGCCAGTAGCTGGGAG 3´ and reverse primer 5´
CAGTTCAAAGATCGGGCAAG 3´. PstI (New England Biolabs) and VspI (Thermo
Fisher Scientific) restriction enzymes were used to digest PCR product from exon 1
and exon 19 region, respectively. Digested PCR products were run in 1.5% agarose
gel stained with ethidium bromide.  The banding pattern of the digested Mlh1+/-
samples were compared to that of the Mlh1+/+ and Mlh1-/- controls. The sample was
considered to have undergone LOH if the banding pattern of Mlh1+/- samples were
identical to the banding pattern of Mlh1-/- control.
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4. RESULTS
4.1. Contribution of Mlh1 gene dosage, age and proliferative capacity
of tissues to MSI (Study I-II)
To investigate how the proliferative capacity of the Mlh1+/- tissues effect the tissue-
specific MSI, we performed highly sensitive SM-PCR based MSI assay in highly
proliferating small intestine (specifically, jejunum) and sperm, and in low proliferating
spleen. We tested MSI at three microsatellite loci, two mononucleotide repeat: A27 and
A33, and a dinucleotide repeat: D14Mit15. The same tissues from age-matched
Mlh1+/+ and Mlh1-/- mice were used as MMR-proficient and MMR-deficient controls,
respectively (with the exception of sperm cells as Mlh1-/- do not produce sperm cells
due to failure in spermatogenesis, see section 1.5.2). This experimental set-up gave
us an added advantage of comparing MSI across specific tissues in the Mlh1-proficient
and Mlh1-deficient system in-vivo. Experiments were carried out in young and old adult
mice (4-and 12-months) which gave us the opportunity to assess contribution of age
to tissue-specific MSI. In addition, the MSI assay was also performed in intestinal tumor
from a 12-month old Mlh1-/- mice.
4.1.1. Highly proliferating Mlh1+/- tissues show MSI at mononucleotide repeats;
dinucleotide repeat was stable (Study I-II)
In Mlh1+/- mice, compared to age-matched Mlh1+/+ mice, we observed increase in
deletions at mononucleotide repeats in small intestine and in sperm (2.2-fold (p =
0.007) and 2.7-fold (p= 0.001) at 4-month, and 4.8-fold (p=0.001) and 2.3-fold
(p=0.003) at 12-month time point, respectively). No such increase was seen in spleen
(see Table 4 for deletion rates). We saw an age-dependent increase in deletions in
Mlh1+/- small intestine and in Mlh1+/- sperm from 4-month to 12-month time point (1.5-
fold (p= 0.006) and 1.3-fold (p=0.008), respectively), while Mlh1+/- spleen did not show
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such age-dependent increase (see Table 4 for deletion rates). The deletions observed
in Mlh1+/- tissues were almost exclusively single repeat unit (i.e.1bp) deletions (Figure
6).
Unlike mononucleotide repeats, the dinucleotide repeat was stable in all the three
Mlh1+/- tissues analyzed at both time points (See table 5 for MSI rates). While Mlh1+/-
sperm and Mlh1+/- spleen showed almost no deletions at D14Mit15, a small number
of deletions were detected at D14Mit15 in Mlh1+/- small intestine, and this number
increased with age. As at the mononucleotide repeats, the deletions detected at
dinucleotide repeat in Mlh1+/- tissues were single repeat unit (i.e. 2bp) deletions
(Figure 6).
One outlier Mlh1+/- mouse was identified. This 4-month old Mlh1+/- mouse showed
substantially higher deletions at mononucleotide repeats in all the three tissues
analyzed (32.8%, 7.9%, and 4.9% in small intestine, sperm and spleen, respectively),
compared to other age-matched Mlh1+/- mice (6-fold, 1.7-fold, and 2-fold higher,
respectively). We also observed slightly elevated deletions at dinucleotide repeat
(3.9%) in small intestine of this mouse. Unlike deletions observed in other Mlh1+/- small
intestine (i.e. single repeat unit deletions), in this mouse a high proportion of 2 repeat
unit deletions was also observed (both at mono- and dinucleotide repeats)
(Supplementary figure 3/I), while sperm and spleen showed only single repeat unit
deletions. This mouse was excluded from all the statistical analysis (both in Study I
and II) and is referred to as “outlier” mouse here forward.
4.1.2. Deletions increase with age and proliferative capacity of tissues in Mlh1-/-
mice (Study I)
Compared to age-matched Mlh1+/+ tissues (which were either microsatellite stable or
showed only baseline level of deletions), Mlh1-/- tissues showed substantially higher
deletions both at mono- and dinucleotide repeats. For mononucleotide repeats, this
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increase was 20.1-fold (p=0.0001) and 14.4-fold (p=0.0001) higher at 4-months, and
58.2-fold (p=0.0001) and 24.1-fold (p=0.0001) higher at 12-months in small intestine
and spleen, respectively, and for the dinucleotide repeat, 56-fold (p=0.0001) and 23.5
(p=0.0001) higher at 4 months and 41-fold (p=0.0001) and 34.5-fold (p=0.0001) higher
at 12-months in small intestine and spleen, respectively) (see Table 4 and 5 for MSI
rates). We also saw an age-wise increase in deletions at both mono- and dinucleotide
repeats in Mlh1-/- tissues from 4 months to 12 months. In Mlh1-/- small intestine this
increase was significant (2-fold (p= 0.01) and 2.2-fold (p= 0.01) at mono- and
dinucleotide repeat, respectively), while in Mlh1-/- spleen it was not (1.6- fold (p= n.s.)
and 1.5-fold (p=n.s.) at mono- and dinucleotide repeat, respectively) (see Table 4 and
5 for MSI rates).
Unlike in Mlh1+/+ and Mlh1+/- tissues, where we observed almost exclusively single
repeat unit deletions, the deletion size shifts in the Mlh1-/- tissues both in small intestine
and in spleen were larger. At 4 months, size shift involved up to 5- and 3-repeat units
at mono-, and 1- and 2-repeat unit at dinucleotide repeats in Mlh1-/- small intestine and
spleen, respectively; single repeat unit deletions were the most prominent type of
mutant allele (Figure 6). The size shifts further increased with age in Mlh1-/- small
intestine, while Mlh1-/- spleen showed similar size-shits as at 4-months, at 12-months,
Mlh1-/- small intestine displayed up to 7- and 3- repeat-unit deletions at mono- and
dinucleotide repeats, respectively (Figure 6).
Deletions were even more frequent in Mlh1-/- intestinal tumor (Figure 6), compared to
macroscopically normal small intestine of 12-month old Mlh1-/- mice, intestinal tumor
from a 12-month old Mlh1-/- mice showed 1.5-fold, and 1.3-fold more deletions at
mono- and dinucleotide repeat, respectively. Similar to the Mlh1-/- small intestine at 12
month time point, the Mlh1-/- intestinal tumor displayed up to 7- and 3- repeat-unit
deletions at mono- and dinucleotide repeats, respectively. Most prominent mutant
alleles in the Mlh1-/- intestinal tumor were 3 and 4-bp deletions at A27, and 1 and 4-bp
at A33, while in Mlh1-/- small intestine it was 1 and 2 bp deletions at both A27 and
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A33).  At D14Mit15, though the prominent allele was 1 repeat-unit deletion in both
tumor and in Mlh1-/- normal intestine, the frequency of 1 repeat-unit deletion further
increased in the tumor compared to the Mlh1-/- normal intestine (Figure 6).
In general, mononucleotide repeats were more unstable than dinucleotide repeat.
Deletions at mononucleotide repeats were approximately 4- to 5-fold higher than at the
dinucleotide repeat both in the Mlh1+/- and the Mlh1-/- tissues (see Table 4 and 5 for
MSI rates).
4.1.3. Opposite dynamics of insertions versus deletions at mononucleotide
repeats in proliferating tissues (Study I-II)
While Mlh1+/+ tissues displayed only baseline levels of deletions (on average 2% and
0.2% at mono- and dinucleotide repeats, respectively), we observed insertional burden
at the mononucleotide repeats (particularly at A33) in Mlh1+/+ tissues. At 4 months,
A27 and A33 showed on average 2%, 4%, 3% and 6%, 8%, 10% insertions in Mlh1+/+
small intestine, sperm and spleen, respectively. In Mlh1+/+ jejunum insertions further
increased with age (for A27 p= n.s., A33 p= 0.01), while in Mlh1+/+ spleen and sperm
insertion frequencies were similar at 4- and 12- month time points (see Table 4 for MSI
rates).
In general, in small intestine and sperm, insertions at mononucleotide repeats (in-
particular at A33) tended to decrease with decreasing Mlh1 gene dosage, especially
at the 12 month time-point, while in spleen no such decrease was observed (see Table
4 for MSI rates). Insertions at mononucleotide repeats further decreased in Mlh1-/-
intestinal tumor to 1.6%. In Mlh1-/- tissues, unlike deletions, insertions were relatively
less affected by age. At the dinucleotide repeat, Mlh1+/+ and Mlh1+/- tissues showed
negligible insertions at both time points, while Mlh1-/- small intestine and Mlh1-/- spleen
showed 2.8% and 2.3%, and 3.8% and 2.7% insertions at 4- and 12-months,
respectively (see Table 5 for MSI rates).
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Figure 6. Heat-map of allele frequency (%) at microsatellite loci A27, A33 and
D14Mit15. Heat-map shows gradual increase in size-shift and in frequencies of
deletion mutants with decreasing Mlh1 gene dosage and with age, severity of which
associates with proliferative capacity of tissues. Deletions further increased in Mlh1-/-
intestinal tumor. Insertions on the other hand were almost exclusively single repeat
unit size-shifts, irrespective of tissue or of genotype. The 4-month old Mlh1 +/- outlier
mouse (see section 4.1.1) was excluded from the heat map (separate heat map for
this mouse is shown in Supplementary figure 3 /I).
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Table 4. Summary of SM-PCR based MSI analysis results at mononucleotide repeats.
Shown is the MSI(%) at A37 and A33 ± SD. Data for 4-month outlier mouse is shown
in separate column.
Table 5. Summary of SM-PCR based MSI analysis results at dinucleotide repeat
D14Mit15. Presented is average MSI(%) ± SD. Data for 4-month outlier mouse is
shown in separate column.
deletions (%) insertions (%)
tissues Mlh1 +/+ Mlh1 +/-
outlier
Mlh1 +/-





jejunum 0.2 ± 0.2 0.7 ± 1.5 3.9 11.2 ± 1.4 0 ± 0 0.2 ± 0.2 0 2.8 ± 0.8
spleen 0.2 ± 0.3 0 ± 0 0 4.7 ± 1.3 0.3 ± 0.5 0 ± 0 0 2.3 ± 1.1
sperm 0 ± 0 0 ± 0 0 NA 0 ± 0 0.2 ± 0.3 0 NA
12 months
jejunum 0.6 ± 0.4 2.3 ± 2.5 24.6 ± 0.2 0 ± 0 0.1 ± 0.1 3.8 ± 0.9
spleen 0 ± 0 0.4 ± 0.6 6.6 ± 1.8 0 ± 0 0 ± 0 2.7± 0.3
sperm 0.2 ± 0.2 0.1 ± 0.2 NA 0 ± 0 0.1 ± 0.2 NA
deletions (%) insertions (%)
tissues Mlh1 +/+ Mlh1 +/-
outlier
Mlh1 +/-





jejunum 2.4 ± 0.5 5.5 ± 1.7 32.8 50 ± 2.5 3.9 ± 0.9 4.2 ± 2.1 1.9 3.7 ± 0.7
spleen 1.8 ± 0.3 1.8 ± 0.6 4.9 26 ± 0.9 6.6 ± 1 5.9 ± 2.1 3.4 8.4 ± 0.7
sperm 1.7 ± 0.7 4.5 ± 0.5 7.9 NA 6 ± 0.6 4 ± 1.1 4.9 NA
12 months
jejunum 1.7 ± 0.2 8.1 ± 2.2 99 ± 5.8 6.3 ± 0.2 3.5 ± 1.3 1.9 ± 0
spleen 1.7 ± 1.0 1.8 ± 0.7 41 ± 5.8 5.2 ± 0.8 5.6 ± 1.2 5.5 ± 0.9
sperm 2.6 ± 0.5 5.9 ± 0.7 NA 6 ± 0.9 4.2 ± 0.7 NA
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4.2. Mlh1+/- mice show sporadic decrease in MLH1 expression levels
in small intestine but not in spleen (Study I)
 Mlh1+/- small intestine (including outlier mouse) showed higher inter-individual
variation in deletion frequencies compared to Mlh1+/- spleens. To assess whether this
inter-individual variation was due to variable Mlh1 expression levels, we quantified
Mlh1 mRNA and MLH1 protein using qPCR and western blot, respectively. Age-
matched spleens which showed minimal MSI in Mlh1+/- mice were used as control
tissue. Wildtype and Mlh1 knockout tissues were used as positive and negative
controls for MLH1 expression, respectively. The qPCR and western blot experiment
were performed in 4- and 12-month time points. We also assessed Mlh1 expression
variation in jejunum of 4-month old Mlh1+/- mice by immunohistochemistry (IHC).
Further, Mlh1 mRNA expression was assayed in additional somatic tissues (namely:
brain, kidney and liver) for a broader view of tissue-specific differences in Mlh1
expression.
Mlh1+/- spleens showed the expected, approximately 50% level of Mlh1+/+ expression
both at the transcript and protein levels at both 4- and 12-month time points (Figure
2A/I and Figure 2B/I). In contrast, Mlh1+/- small intestine showed lower than expected
Mlh1 mRNA and MLH1 protein expression compared to Mlh1+/+ expression (Figure
2A/I and Figure 2B/I). At 4 months, compared to the wildtype expression, the average
Mlh1 mRNA and Mlh1 protein expression in the Mlh1+/- small intestine were 26%
(range: 8%-46%) and 24% (range: 0.4%-53%), respectively, and at 12 months, 15%
(range: 9%-23%) and 17% (range: 0.2%-29%), respectively (Figure 2A/I and Figure
2B/I). Mlh1 expression decreased in Mlh1+/- small intestine with age (from 4- to 12-
month time point), however, the decrease was not statistically significant. Further, we
assessed Mlh1 mRNA expression in small intestine of 1-month old Mlh1+/- mice.
Compared to the 1-month time point, Mlh1+/- small intestines at 12-month time point
showed significant decrease in Mlh1 mRNA levels (p=0.0283), while Mlh1+/- spleens
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at the 1-month time point (like 4- and 12- month time point) showed the expected
approximately 50% of wildtype Mlh1 mRNA levels (Supplementary figure 4/I). In
addition to Mlh1+/- spleen and Mlh1+/- small intestine, we quantified Mlh1 mRNA
expression also in brain, kidney and liver of 4-month old Mlh1+/- mice. All three of the
assayed Mlh1+/- tissues showed the expected Mlh1 mRNA expression (60%, 56% and
56% compared to Mlh1+/+ tissues, respectively) (Supplementary figure 5/I).
Based on the MLH1 protein expression levels in the small intestine, Mlh1+/- mice could
be divided into two groups, from here onward termed as Mlh1+/- MLH1normal and Mlh1+/-
MLH1low and defined by comparatively higher MLH1 protein levels (approximately 50%
of the wildtype MLH1 expression, range: 18-53% and 19-32% at 4- and 2-month time
points, respectively), versus lower MLH1 protein levels (less than 4% at both time
points) in small intestine, respectively (see histogram of Figure 2B/I). 7 and 5 out of
12 4-month Mlh1+/- mice, and 7 and 4 out of 10 12-month Mlh1+/- mice assayed were
categorized as Mlh1+/- MLH1normal and Mlh1+/- MLH1low mice, respectively.
To complement protein expression analysis by western blot, we also performed IHC in
small intestine of 4-month old mice. Upon automated quantification and scoring of the
staining intensities by IHC profiler (a plug-in in ImageJ software), 3 out of 6 (50%) of
the Mlh1+/- small intestine was scored as MLH1 low-positive, while other 50% of
Mlh1+/- small intestine was scored as MLH1-positive (Figure 2C/I). Further, assessing
the MLH1 staining in the crypt and in the villi separately with IHC, we discovered that
MLH1 expression decreased in MLH1 low-positive Mlh1+/- small intestine both in the
crypt and in the villi, and that MLH1-negative cells were exclusive to villi
(Supplementary figure 6/I).
In brief, with exception of the Mlh1+/- small intestine, all Mlh1+/- tissues tested (spleen,
brain, kidney and liver) showed the expected, approximately 50% reduced Mlh1
expression levels compared to wildtype. In Mlh1+/- small intestine, substantial numbers
of Mlh1+/- mice showed lower than expected levels of MLH1 expression, some with
undetectable levels of MLH1.
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4.3. Depletion of MLH1 in small intestine of Mlh1+/- mice associates
with soma-wide Mlh1 promoter methylation (Study I-II)
To investigate possible underlying causes of sporadic tissue-specific MLH1 depletion
in Mlh1+/- jejunum, we tested for genetic (LOH) and epigenetic (Mlh1 promoter
methylation) mechanisms known to effect the MLH1 expression using RFLP and MSP
assay, respectively.
Only one (the 4-month old outlier Mlh1+/- mice) out of 22 Mlh1+/- mice tested showed
LOH in small intestine (Figure 3B/I). All other Mlh1+/- mice retained the Mlh1+/+ allele
in small intestine (Figure 3B/I and Supplementary figure 8/I). Surprisingly, a
significant number of Mlh1+/- mice (16 of 22) showed Mlh1 promoter methylation in
normal jejunum and spleen. Upon assaying Mlh1 promoter methylation status in other
tissues (namely: brain and sperm), we found Mlh1 promoter methylated in both the
tested tissues (Supplementary figure 10/I, Figure 2/II and Supplementary figure
4/II). All the observed Mlh1 promoter methylation was partial, i.e. DNA fractions both
with and without Mlh1 promoter methylation were detected. Further, Mlh1-/- mice also
showed the similar (i.e. partial) Mlh1 promoter methylation in all tissues analyzed, while
none of the tissues tested in Mlh1+/+ mice showed Mlh1 promoter methylation (Figure
3C/I, Supplementary figure 10/I, Figure 2/II and Supplementary figure 4/II).
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4.4. MSI correlates with decreased MLH1 protein levels in small
intestine of Mlh1+/- mice (Study I-II)
We also studied the correlation between MLH1 protein levels and deletions (at
mononucleotide repeats) in Mlh1+/- small intestine and spleens. At the 4-month time
point, small intestine of Mlh1+/- MLH1normal and Mlh1+/- MLH1low mice showed close-to-
expected (35%) and very low (2%) average MLH1 protein expression, and displayed
3.9% and 7.2% deletions, respectively (See Table 6 and Figure 4/I). At the 12-month
time point, small intestine of Mlh1+/- MLH1normal and Mlh1+/- MLH1low mice showed
lower-than-expected (24%) and very low (1%) average MLH1 protein expression, and
exhibited 6.6% and 11.2% deletions, respectively (see Figure 4/I). The Mlh1+/- outlier
mouse had almost no detectable MLH1 protein expression in its jejunum and displayed
32.8% deletions (see Figure 4/I). Compared to 4 months, Mlh1+/- MLH1normal mice at
12 month time point showed 1.5-fold decrease in MLH1 expression and showed 1.7-
fold increase in deletions (see Figure 4/I). Mlh1+/- MLH1low mice at 12 months showed
1.5-fold higher deletions than at 4-month time point, while the MLH1 expression levels
between the two groups were comparable. All Mlh1+/- spleen samples (at both time
points) showed expected levels (i.e. approximately half of wildtype MLH1 expression),
and comparable deletions to Mlh1+/+ spleen, except in the outlier Mlh1+/- mouse which
showed a 2-fold increase in deletions in spleen compared to age-matched Mlh1+/-
spleens, despite having normal protein expression level (Supplementary Figure 12/I).
We also performed linear regression analysis to study the correlation of MLH1 protein
expression and MSI rates in the small intestine. The Mlh1+/- small intestine were
clustered into two distinct groups. MLH1 protein expression levels inversely correlated
with deletion rates at both the time points (R2 = 0.5, p= 0.001 and R2 = 0.46, p= 0.01
for 4- and 12- month time point, respectively) (Supplementary Figure 11/I).
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Table 6. Comparison of MLH1 expression levels and deletion frequencies in small
intestine of MLH1normal and MLH1low Mlh1+/- mice.
MLH1normal MLH1low
average (%) range (%) average (%) range (%)
4 months
MLH1 protein level 35 27 - 53 2 0 - 4
deletions 3.9 2.8 - 4.4 7.2 5.6 - 8.8
12 months
MLH1 protein level 24 18 - 29 1 1 - 2
deletions 6.6 5.7 - 7.7 11.2 9.8 - 12.7
We grouped the Mlh1+/- sperm samples based on the Mlh1+/- MLH1normal and Mlh1+/-
MLH1low classification. Unlike in the small intestine, there was no substantial difference
in sperm DNA deletions between the two Mlh1+/- sub groups. However, Mlh1+/- mice
with soma-wide Mlh1 promoter methylation in general showed higher deletion rate in
sperm (Figure 7).
Figure 7. Sperm of MLH1normal and MLH1low Mlh1+/- mice show comparable
deletions at mononucleotide repeats. “M” indicates sperm with Mlh1 promoter
methylation. Arrow indicates the outlier Mlh1+/- mouse.
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5. DISCUSSION
Individuals with an inherited mutant MMR allele are born with one functional copy of
the MMR gene and their tissues are thought to be microsatellite stable. LS associated
CRCs are MMR-deficient and show MSI-high phenotype, which led to the notion that
MSI occurs only after complete loss of MMR (i.e. after the “second hit” of the MMR
genes) (Aaltonen et al., 1993; Hemminki et al., 1994). Evidence of LS-associated
adenomas retaining (some) MMR protein expression suggests that the second hit may
occur later in the multi-step tumorigenesis than previously anticipated, however these
adenomas were classified as microsatellite stable (Valo et al., 2015). Other clues
suggest that MSI may occur (rather early) in presence of MMR. For example, low-level
MSI in seen in peripheral blood leukocytes (PBLs) of LS individuals (Alazzouzi et al.,
2005; M. I. Coolbaugh-Murphy et al., 2010), MSI in normal colon mucosa of LS
individuals with minimal MMR expression (Parsons et al., 1995)). We showed that if
sufficiently sensitive assays are used, MSI is detectable pre-neoplastic normal tissues
in vivo in the presence of MMR. Our approach of assaying MSI at highly unstable
microsatellites in single DNA-molecule level detects MSI lower than 1%, while
standard MSI assays (which use bulk DNA) have a sensitivity limit of 20-25 % MSI (M.
Coolbaugh-Murphy et al., 2004). Our highly sensitive SM-PCR assay can quantify
baseline levels of MSI even in Mlh1+/+ tissues. We showed that MSI, particularity
deletions at microsatellites is dependent on MLH1 protein levels in somatic tissues.
Mlh1-/- tissues showed high-level of MSI, while Mlh1+/+ tissues were microsatellite
stable or showed base-line levels of deletions. In highly proliferating Mlh1+/- small
intestine, we showed a sporadic MLH1 depletion and elevated MSI, while no such
MLH1 level aberration was observed in Mlh1+/- spleens and was microsatellite stable.
In Mlh1+/- small intestine, firstly, we showed that Mlh1+/- mice with close to expected
MMR protein levels (i.e. approximately 50% of the wildtype expression) exhibit MSI in
the small intestine, providing evidence of tissue-specific Mlh1 haploinsufficiency.
Secondly, MSI further increases with sporadic decrease in MLH1 protein levels in the
Mlh1+/- small intestine. In Mlh1+/- small intestine, we observed a critical threshold of
MLH1 protein level (18% compared to wildtype expression) below which MSI
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exacerbates. Similar critical threshold and loss of MMR function was reported in vitro
by Kansikas et. al., they reported loss of MMR function below 23% Mlh1 mRNA
expression level (Kansikas, Kasela, Kantelinen, & Nystrom, 2014). Our results show
that small intestine in Mlh1+/- mice is particularly prone to aberrant MLH1 depletion,
and that normal small intestine of Mlh1+/- mice show MSI. Likely similar pre-neoplastic
cellular aberrations occur in the GI tract of LS individuals, instigating GI tract
tumorigenesis.
We did not observed any tumor in the small intestine of Mlh1+/- mice. What we have
reported here (MSI readouts at non-exonic microsatellites) likely represents early-
stage pre-tumorigenic genomic instability. MSI per se does not necessary lead to
tumorigenesis (Prolla et al., 1998). For tumorigenesis to initiate, MSI should occur in
exonic microsatellites (i.e. in the MSI-target genes) (Duval & Hamelin, 2002; Vilkki et
al., 2002). MSI in exonic microsatellites could alter gene function and instigate
tumorigenesis (Duval & Hamelin, 2002). The exons are better protected by the MMR
(Frigola et al., 2017) than other genic regions, thus, exons are unlikely to accumulate
early mutations which could be catastrophic to the cells. We focused our study on non-
exonic microsatellites which are less protected by MMR due to differential MMR
(Frigola et al., 2017), making them more sensitive indicator of MMR defects. This gave
us the advantage of detecting early-stage pre-tumorigenic MSI. Although we did not
observe any tumor in Mlh1+/- small intestines, we uncovered large inter-individual
variation in MSI in normal (non-neoplastic) small intestine of Mlh1+/- mice, ranging from
MSI comparable to Mlh1+/+ to that in Mlh1-/- small intestine. We also observed an age-
dependent increase in MSI levels in Mlh1+/- small intestine. Moreover, an appreciable
fraction (42%) of young (4-months) Mlh1+/- mice showed MSI levels in their pre-
neoplastic small intestine comparable to old (12-months) Mlh1+/- mice. Similar
observations i.e. some young individuals showing elevated MSI were reported in
peripheral blood leukocyte DNA of LS patients (M. I. Coolbaugh-Murphy et al., 2010).
Further, one 4-month old Mlh1+/- mice showed high MSI in its (normal and tumor-free)
small intestine, comparable to MSI in age-matched Mlh1-/- small intestine and higher
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than MSI observed in 12-month Mlh1+/- small intestine. If this mouse was aged more
it would have likely accumulated mutations in the MSI-target genes triggering
tumorigenesis in the GI tract. In addition, 30% of Mlh1+/- mice died in our colony before
they were used in experiments but were not examined post-mortem (see Kaplan-meier
survival curve in Supplementary figure 13/I). Likely some, if not all, of these Mlh1+/-
mice died because of MMR-associated tumors. Overall, our results show that Mlh1+/-
small intestine is susceptible to tissue-specific pre-neoplastic MSI in vivo, accumulation
of which starts already at a young age and varies substantially between individuals.
We observed MSI in germline cells (sperm) of Mlh1+/- mice, and MSI increased with
age. A mature sperm cell is a product of multiple cell divisions (a spermatogonial stem
cell (SSC) undergoes up to 12 cell divisions to produce a mature sperm). In such a
highly proliferating system the likelihood of accumulating replication error increases
with each round of DNA replication, thus MSI in Mlh1+/- sperm is not surprising.
Comparing MSI in sperm to that of the somatic tissues (jejunum and spleen) of the
same Mlh1+/- mice, all Mlh1+/- mice showed higher MSI in sperm compared to spleen.
Compared to small intestine, 44% of Mlh1+/- mice showed similar levels of MSI in their
sperm, while in the remaining Mlh1+/- mice (56%) small intestine showed higher MSI
than sperm (Figure 8). A likely explanation of sporadic increase in MSI in small
intestine compared to sperm of Mlh1+/- mice is our observation of sporadic decrease
in MLH1 levels in small intestine. Although we did not measure MLH1 levels in testis,
since we did not observe sporadic increase in MSI levels in Mlh1+/- sperm, equitable
assumption is that MLH1 levels in Mlh1+/- testis is normal (i.e. approximately 50% of
the wildtype). Under this assumption Mlh1+/- testis are also haploinsufficient as Mlh1+/-
sperm showed increased MSI compared to Mlh1+/+ sperm despite possibly having
normal MLH1 levels in testis, which needs further investigation. Further, the age when
intestine stem cells (ISCs) and SSCs start to proliferate is different. SSCs are in
dormant stage (i.e. do not proliferate) until puberty (approximately 4-5 week in male
mice, and 15 years in human), but ISCs start to proliferate between E16.5 and
postnatal day 7 in mice (Barker, 2014) and already in embryonic stage (week 9-10 of
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gestation in human (Drozdowski, Clandinin, & Thomson, 2010). Given that ISCs start
to proliferate much earlier in life, and that they have a very high proliferation rate (300
million new epithelial cells are generated every day) (Barker, 2014), by the time SSCs
start to proliferate, cells in the small intestine have had numerous opportunities to
accumulate mutations. Likely explaining the sporadic increase in MSI in Mlh1+/- small
intestine compared to Mlh1+/- sperm. Unlike Mlh1+/- small intestine where we observed
substantial inter-individual variation in MSI, Mlh1+/- sperm did not show such drastic
inter-individual variation (expect the outlier Mlh1+/- mouse). Overall, our results
indicate that in the Mlh1 heterozygous condition, the MMR repair activity is
compromised to the extent that it is unable to maintain wildtype-level genome stability
in highly proliferating somatic and germline cells.
Figure 8. Comparison of tissue-specific deletions at mononucleotide repeats.
Highly proliferative small intestine and sperm show higher deletions at mononucleotide
repeats than the low proliferating spleen. Further, small intestine show sporadic
increase in the deletions in some Mlh1+/- mice with soma-wide Mlh1 promoter
methylation (indicated by “M”). Arrow head indicates the outlier mice which showed
high MSI in small intestine. Asterisk indicates no data.
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We observed mononucleotide repeats are more unstable than the dinucleotide repeat,
similar observations has been reported by others (Bacher, Abdel Megid, Kent-First, &
Halberg, 2005; Kabbarah et al., 2003). Our result highlights the importance of selecting
appropriate microsatellite loci especially for detection subtle MSI phenotype.
Interestingly, we found different dynamics of insertions versus deletions at the
mononucleotide repeats. Firstly, we observed an insertional bias (particularly at A33)
in wildtype tissues (both in germline and somatic cells) while deletions were negligible.
Secondly, in highly proliferating tissues, deletions tended to increase with deceasing
Mlh1 gene dosage while insertions showed the opposite trend; low proliferating spleen,
on the other hand, did not show such Mlh1-dosage dependent fluctuations in MSI.
Further, while we observed almost exclusively single repeat unit (i.e. 1bp) insertions
irrelevant of tissue type or gene dosage, deletion-allele size increased with decreasing
Mlh1 dosage in proliferating tissues. Like in normal tissues, the Mlh1-deficient intestinal
tumor also displayed a high level of deletions and almost no detectable insertions.
As the endogenous source of insertions and deletions at microsatellites is the same
(i.e. replication errors made by the faulty DNA polymerase), one would expect the
likelihood of insertions and deletions at microsatellites to be similar. However, we saw
clear opposite dynamics of insertions versus deletions at the mononucleotide repeats
in proliferating tissues. DNA loop formation due to replication slippage in the nascent
or template strand gives rises to insertion or deletion at microsatellites, respectively
(see Figure 3). Post-replication these indels should be repaired by MMR. Our
observation of insertional burden but minimal deletion in wildtype tissues implies
formation of DNA loops primarily occur on the nascent strand and/or less efficient
repair of insertions by MMR. Lower insertion rates in Mlh1 hetero- and homozygous
tissues can be likely explained by deletion events erasing many of the insertions that
occurred in the earlier cell division converting the 1bp insertion mutant alleles into wild-
type alleles.
We detected Mlh1 promoter methylation in Mlh1+/- and Mlh1-/- tissues originating from
all embryonic layers: endoderm (jejunum), ectoderm (brain) and mesoderm (spleen),
which indicates that Mlh1 promoter methylation has occurred in the germline or in the
early-post-zygotic stage as suggested by others who observed the same phenotype in
multiple human tissues (Niessen et al., 2009). Also, we observed Mlh1 promoter
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methylation in Mlh1+/- sperm. Ours is the first observation of soma-wide Mlh1 promoter
methylation phenotype in a MMR mouse model. In human, this phenotype has been
reported in LS (suspected) patients (Suter et al., 2004). Despite observing Mlh1
promoter methylation in multiple tissues of Mlh1+/- mice, we observed MLH1 depletion
only in the Mlh1+/- small intestine, thus Mlh1 promoter methylation cannot by itself
account to lower MLH1 levels in small intestine. Most likely there are other regulatory
mechanism/s unknown so far that govern the MMR protein levels in the GI tract which
needs further investigation.
LS (suspected) patients and LS patients both have the same tumor spectra, however
LS (suspected) patients have relatively early onset of tumor compared to the LS
patients. In our study, elevated MSI in Mlh1+/- proliferating tissues associated with
Mlh1 promoter methylation. It is likely that LS (suspected) patients also have relatively
earlier accumulation of MSI compared to LS patients, leading to early appearance of
tumor compared to the LS patients. In addition, sperm in LS (suspected) patients are
also reported to exhibit Mlh1 promoter methylation (Suter et al., 2004). We show that
Mlh1 promoter methylation in Mlh1+/- sperm associates with MSI in the Mlh1+/- sperm.
Human studies have shown a high association of single nucleotide polymorphism
(SNP) in Mlh1 promoter and the occurrence of Mlh1 promoter methylation (Suter et al.,
2004). Our study mice were a cross of C57BL/6J and 129S1/SvImJ mouse strains.
These mice have SNPs in and around the core promoter, and it is possible that there
is preferential methylation of Mlh1 promoter in one of the two alleles (either C57BL/6J
or 129S1/SvImJ), which needs further investigation. Our observation of constitutive
Mlh1 promoter methylation in Mlh1-/- mice (mice of 129S1/SvImJ background), and no
Mlh1 promoter methylation in the tissues analyzed in the Mlh1+/+ mice (mice of
C57BL/6J background) indicates that Mlh1-/- allele is preferentially methylated.
Further, LOH was observed in only one (of 22) Mlh1+/- mice, indicating that Mlh1
promoter methylation is an earlier and more common event than LOH in multi-step
tumorigenesis at least in this mouse model. Overall we found that Mlh1+/- mice exhibit
MSI in proliferating normal (non-neoplastic) somatic tissue (small intestine) and in
germline cells. Further, we observed age independent sporadic MLH1 depletion in the
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normal small intestine and elevated MSI in the normal small intestine of these mice.
Mlh1 promoter methylation only affected MLH1 protein expression in small intestine of
the Mlh1+/- mice and not the other tissues assayed, as such, Mlh1 promoter
methylation (at least not alone) cannot explain MLH1 protein depletion in the small
intestine, however the observation of Mlh1 promoter methylation, MLH1 protein level
depletion, and MSI in Mlh1+/- small intestine indicate these observation are very-early
pre-tumorigenic event.
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6. CONCLUSION AND FUTURE PROSPECTIVE
My thesis presents a comprehensive study on the effect of MMR heterozygosity on
somatic and germline genomic instability. Further, my thesis elucidates the correlation
between tissue-specific genomic instability and MMR expression levels in somatic
tissues with variable (i.e. high and low) proliferation rates.
Using a highly sensitive single-molecule PCR based MSI assay, we were able to detect
MSI in Mlh1+/- tissues; we showed that highly proliferating Mlh1+/- small intestine and
Mlh1+/- sperm display MSI which increases with age, while the low proliferating spleen
was microsatellite stable. Further, we show that the microsatellites (in particular
mononucleotide repeats) are more prone to deletions. In addition, we show that soma-
wide Mlh1 promoter methylation is common in Mlh1+/- mice and associates with
observed MSI in proliferating tissues.
Further, investigating the relationship between tissue-specific MLH1 expression and
MSI in somatic tissues, we show that specifically the Mlh1+/- small intestine is
vulnerable to elevated MSI, which seems to depend on a critical threshold of MLH1
protein level, and is age-independent. Firstly, we showed that the Mlh1+/- small
intestine expressing close to expected MLH1 levels (i.e. approximately 50% of
wildtype) display MSI, implying MMR haploinsufficiency in normal, tumor-free Mlh1+/-
intestine. Secondly, we show that when MLH1 expression reaches a critical threshold
(below approximately 20% of Mlh1+/+ expression), MSI (particularly deletions)
substantially increases in the Mlh1+/- intestine.
Overall, we showed that the aberrant molecular phenotypes displayed by MMR-
associated tumor (namely: MSI, Mlh1 promoter methylation and MMR-deficiency) is
seen, though at relatively low levels, in normal, tumor-free Mlh1+/- intestine at a young
age. Thus, these phenotypes, previously considered as cancer-associated events
occurs very early as a tumor precursors in a tissue-specific manner, which likely
explains why the GI tract of LS individuals are particularly prone to MSI-high tumors.
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